All In Biotech

Drug Trial Radar · NCT06251947

Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen

A Study of Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen With Risk Factors:A Single-Arm, Multicenter Clinical Trial

Last checked: Nov 20, 2026Latest source record: May 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

83

Planned (sponsor's estimate)

Start

Apr 15, 2024

Primary completion

Jun 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Shandong UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
First posted
Feb 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study was to observe the efficacy and safety of Efbemalenograstim Alfa in the prevention of absolute neutrophil count (ANC) reduction after chemotherapy in Ovarian and Cervical cancer patients at risk of platinum-containing chemotherapy with risk factors in febrile neutropenia (FN).

Conditions

  • Ovarian Cancer
  • Cervical Cancer

Interventions

  • Efbemalenograstim AlfaDrug

    Efbemalenograstim Alfa is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of grade 3/4 neutropeniaTime frame: At the first of cycle 1 (each cycle is 21 days)

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Xiangya Hospital, Central South University,

    Changsha, Hunan, China · Not yet recruiting

  • Zhongda Hospital, School of Medicine, Southeast University

    Nanjing, Jiangsu, China · Not yet recruiting

  • Qilu Hospital of Shandong University

    Jinan, Shandong, China · Recruiting

  • Qingdao Central Hospital, The Second Affiliated Hospital of Medical College of Qingdao University,

    Qingdao, Shandong, China · Not yet recruiting

  • Shanxi Provincial Cancer Hospital

    Taiyuan, Shanxi, China · Not yet recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.